We’re thrilled to announce the promotion of Regina Graul to CEO, President, and member of our Board of Directors. In less than a year, she has strengthened all aspects of the company. She has been working closely with the Board to prioritize building shareholder value by reducing Cyclerion’s operating costs while leading a world-class search and evaluation team, currently triaging multiple business development prospects for which Cyclerion believes it is well suited. Learn more: https://lnkd.in/dc45SJjk
Cyclerion
生物技术研究
Cambridge，MA 3,842 位关注者
We are a biopharmaceutical company on a mission to develop treatments for serious diseases.
关于我们
Our current portfolio includes novel clinical-stage assets, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is exclusively licensed to Akebia and is being advanced in rare kidney disease. Olinciguat is a vascular sGC stimulator that Cyclerion intends to develop itself or out-license for cardiovascular diseases. Concurrently, we are also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments. In addition, Cyclerion holds 10 percent equity ownership in Tisento Therapeutics as part of an asset purchase agreement in which Tisento acquired the brain-penetrant sGC stimulators zagociguat and CY3018.
- 网站
-
https://www.cyclerion.com
Cyclerion的外部链接
- 所属行业
- 生物技术研究
- 规模
- 1 人
- 总部
- Cambridge，MA
- 类型
- 上市公司
- 创立
- 2019
地点
-
主要
获取路线
US，MA，Cambridge，02142
Cyclerion员工
动态
-
We’re excited to announce the appointment of Regina Graul as the new president of Cyclerion! Dr. Graul is a drug hunter with more than two decades of experience leading R&D portfolios in various therapeutic areas and building high-performing cross-functional teams. She has worked across the industry from bench scientist to business development to strategic program leadership and has?shepherded multiple programs into and through clinical development. As the former olinciguat program lead at Cyclerion, she also knows our current assets inside and out. Our founding CEO Peter Hecht has completed his transitional assignment and is stepping away from an operational role at Cyclerion in order to focus on his role as chief executive officer of Tisento Therapeutics, which recently launched with the purchase of promising CNS-focused sGC stimulator assets from Cyclerion. Peter remains a member of our board of directors and looks forward to working closely with Regina as well as our other board members, including the recently announced additions of Dina Katabi and Michael Higgins, to advance our mission of developing treatments for serious diseases. Learn more: https://lnkd.in/dvSSthSN
-